European Stocks Are Little Changed Before U.S.

New Post Public Reply Private Reply Replies (0) Message Board
Stock Buff

European Stocks Are Little Changed Before U.S. Report

European stocks were little changed as investors awaited a U.S. consumer spending report to help gauge the strength of the world’s largest economy. U.S. futures were also little changed, while Asian shares gained.

Adidas AG (ADS) advanced after the sporting goods maker raised its 2012 earnings forecast. Actelion Ltd. (ATLN) soared 18 percent after the company’s lung drug met the main goal of a late-stage clinical trial. Anheuser-Busch InBev NV (ABI) retreated 2.1 percent as revenue fell short of analyst estimates.

The benchmark Stoxx Europe 600 Index fell 0.2 percent to 258.49 at 11:11 a.m. in London after earlier rallying as much as 0.4 percent. Futures on the Standard & Poor’s 500 Index lost 0.2 percent, while the MSCI Asia Pacific Index rallied 0.7 percent.

“There is a two-way pull in the market at the moment,” said Kevin Lilley, a European fund manager at Old Mutual Asset Managers U.K. in London which has 4 billion pounds ($6.5 billion) in assets under management. “On the one hand, company results coming through are generally better than expected on both sides of the Atlantic, and on the other hand, economic data has been mixed.”

Today’s U.S. report may show household purchases, which account for about 70 percent of the economy, rose 0.4 percent in March, according to the median economist forecast in a Bloomberg News survey. That follows a 0.8 percent gain that was the most in seven months. A separate report may show an index of business activity cooled this month.

Spanish GDP

The Stoxx 600 initially climbed at the open after data showed Spain’s economy contracted less than previously forecast in the first quarter as the economy officially entered its second recession since 2009.

Gross domestic product fell 0.3 percent, the same as in the previous three months, the Madrid-based National Statistics Institute said in an e-mailed statement today. That compares with the Bank of Spain’s estimate on April 23 of a 0.4 percent decline. From a year ago, GDP fell 0.4 percent, INE said.

European (SXXP) stocks have climbed for two consecutive weeks as better-than-forecast earnings outweighed disappointing economic data and political uncertainty in France and the Netherlands. The gauge has still lost 5.1 percent since its 2012 high and 1.8 percent this month amid renewed concerns that the euro-area is yet to contain its sovereign-debt crisis.

Adidas Gains

Adidas rose 5.3 percent to 62.97 euros after forecasting a 12 percent to 17 percent increase in full-year profit, compared with a previous prediction of 10 percent to 15 percent growth.

The world’s second-largest sporting-goods maker also today reported a 38 percent jump in net income to 289 million euros ($383 million) in the first three months of the year fueled by golf sales and growth in China . That beat the 230.6 million-euro average analyst estimate in a Bloomberg survey.

Actelion soared 18 percent to 40.02 Swiss francs after its experimental lung drug macitentan met the main goal of a late- stage clinical trial, providing the company with a possible successor to a treatment that accounts for 89 percent of sales.

Telenor ASA (TEL) rallied 3.9 percent to 103.90 kroner as the company said it may have to exit India , the world’s second- largest mobile market, after the country’s telecommunications regulator proposed an 11-fold increase in license fees.

Aberdeen Asset Management Plc (ADN) climbed 2.3 percent to 280.4 pence after first-half revenue and earnings beat market estimates.

Adjusted earnings before amortization for the six months ended March 31 rose to 162.2 million pounds ($264.3 million), or 10.4 pence a share, from 142.8 million pounds, or 8.9 pence, a year earlier, the Scottish money manager said in a statement today. That beat the average estimate of 151.7 million pounds of seven analysts surveyed by Bloomberg.

InBev Declines

InBev paced declining shares, falling 2.1 percent to 53.92 euros. The world’s biggest brewer reported a 6.2 percent rise in first-quarter revenue, excluding acquisitions, disposals and currency fluctuations. The median estimate of eight analysts was for a 6.6 percent increase and represented a 1.8 percent advance in the volume of beer sold. BNP Paribas SA (BNP) , France’s largest bank, lost 0.7 percent to 30.83 euros and Deutsche Bank AG (DBK) slid 0.9 percent to 33.22 euros as Citigroup Inc. said Moody’s Investors Services will likely downgrade major capital market banks including BNP and Deutsche Bank to A2 from A.

Aquarius Platinum Ltd. (AQP) sank 10 percent to 130 pence, snapping a three-day rally. The fourth-largest platinum producer reported a 7 percent drop in attributable output for the third quarter. The company has also suspended the Siphumelele shaft and the M5 project at its Marikana operations in South Africa because of low local-currency prices for its metals.

To contact the reporter on this story: Sarah Jones in London at sjones35@bloomberg.net

To contact the editor responsible for this story: Andrew Rummer at arummer@bloomberg.net

http://www.bloomberg.com/news/2012-04-30/euro...eport.html

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Step Inside Henson's Creature Shop Magic in NYC

Updated Category News Views 8

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

Continue Reading
Streamlined AI Video Analytics for Public Safety Unveiled

Updated Category News Views 2

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

Continue Reading
Lick the Plate Hits 2,000 Shows with Clown Band

Updated Category News Views 5

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 4

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
Oil Markets Shift Focus: Pipelines Trump Drilling

Updated Category News Views 5

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Continue Reading
Crystal Risotti: Leading IT Compliance in Healthcare

Updated Category News Views 6

A Journey Marked by Dedication and Expertise In the demanding world of healthcare technology, where regulations can make or break a company, Crystal Risotti has carved out a space for herself as a leader. Over the last 30 years, she's developed a reputation for blending regulatory expertise with practical business strategies. Her recognition as a Pinnacle Professional of...

Continue Reading
Bitwise Pulls Plug on Dogecoin ETF Amid Market Risks

Updated Category News Views 8

Bitwise Ditches Dogecoin ETF: End of a Speculative Era Who knew that a digital asset inspired by an internet meme would get a platform on Wall Street? Well, Bitwise did. They rallied behind Dogecoin, launching the Bitwise Dogecoin ETF, ticker BWOW. But as of September 10, 2026, the fund's journey is coming to an end with liquidation just around the corner. What Sparked...

Continue Reading
XKL Delivers MediaLight for High-Speed Optical Transport

Updated Category News Views 5

Unpacking the MediaLight Launch Kicking off September, XKL is tossing its hat in the ring with the MediaLight Xponder and Muxponder systems. These aren't just any run-of-the-mill gizmos—nope, they're touted as top-of-the-line optical transport solutions. The talk of the town is their ability to dish out high-density 100G and 400G transport, and for geeks in the trade,...

Continue Reading
Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Updated Category News Views 4

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...

Continue Reading
Fermi's Founder Pushes for Board Overhaul: What's Next?

Updated Category News Views 2

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Continue Reading

Top 5 Most Recently Viewed Articles

LenioBio and ReciBioPharm Team Up for Vaccine Tech Advancement

Updated Category News Views 52

LenioBio and ReciBioPharm Team Up for Vaccine Tech Advancement LenioBio, known for its innovative approaches to rapid protein expression, has announced an exciting collaboration with ReciBioPharm, aiming to boost vaccine production and efficiency through advanced technology. This partnership is set to play a vital role in enhancing the capabilities of protein...

Continue Reading
Trump and Cuban's Rivalry Heats Up Amid Tariff Controversy

Updated Category News Views 172

Trump and Cuban's Feud Intensifies Donald Trump recently directed a fierce critique at billionaire Mark Cuban, accusing him of being a "loser" and labeling him as a "weak and pathetic bully." This latest insult arises from a public dispute ignited by Cuban's criticisms regarding Trump's proposed tariff strategies. The Catalyst of the Conflict The discord took a public...

Continue Reading
Cascale Revamps Engagement Model to Enhance Manufacturer Input

Updated Category News Views 77

Cascale Unveils New Membership Engagement Model Cascale, known previously as the Sustainable Apparel Coalition, is implementing a revolutionary member engagement and governance model aimed at ensuring comprehensive participation across its platform. This initiative emphasizes the vital role of suppliers and manufacturers, thereby enhancing decision-making processes within...

Continue Reading
Cosmic Crisp® Joins Forces with Dunford® for Delicious Pastries

Updated Category News Views 283

Cosmic Crisp® Collaborates with Dunford® for New Dessert Launch Cosmic Crisp® is making waves in the dessert market with an exciting collaboration with Dunford®, a brand celebrated for its exquisite pastries. Let’s explore this innovative partnership that introduces unique experiences for dessert lovers. The Launch of a New Pastry Delight The partnership between...

Continue Reading
Silexion Therapeutics Engages Investors with Public Offering

Updated Category News Views 138

Silexion Therapeutics Engages Investors with Public Offering Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotech company focused on developing groundbreaking RNA interference (RNAi) therapies aimed at treating KRAS-driven cancers. Recently, the company announced closing a public offering priced at $1.35 per share, allowing investors to acquire a total of...

Continue Reading